Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating fungal keratitis

A technology for fungal keratitis and a composition, applied in the field of medical preparations, can solve problems such as toxic and side effects, and achieve the effects of reduced dosage, good therapeutic effect and enhanced bacteriostatic effect

Inactive Publication Date: 2012-01-04
河南省眼科研究所
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to solve the problem of toxic and side effects caused by using thimerosal alone in the treatment of fungal keratitis, the purpose of the present invention is to provide a high-efficiency, broad-spectrum, low-toxicity pharmaceutical composition for the treatment of fungal keratoconjunctivitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating fungal keratitis
  • Medicine composition for treating fungal keratitis
  • Medicine composition for treating fungal keratitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Take 0.0005 g of thimerosal, 0.005 g of benzalkonium chloride or benzalkonium bromide, 0.8 g of sodium chloride, and 0.1 g of sodium hyaluronate, and add water for injection to make up to 100 ml. Filter, sterilize with flowing steam at 100°C, and dispense into eye drops bottles under aseptic conditions.

Embodiment 2

[0020] Example 2: The antifungal pharmaceutical composition consists of 1 gram of thimerosal and 1 gram of benzalkonium chloride or benzalkonium bromide. The preparation process is the same as in Example 1.

Embodiment 3

[0021] Example 3: The antifungal pharmaceutical composition consists of 1 gram of thimerosal and 50 grams of benzalkonium chloride or benzalkonium bromide. The preparation process is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition for treating fungal keratitis, which comprises thiomersalate and benzalkonium chloride or benzalkonium bromide. The weight ratio of the thiomersalate to the benzalkonium chloride or the benzalkonium bromide is 1: (1-50). Action mechanisms of the thiomersalate and the benzalkonium chloride or the benzalkonium bromide for inhibiting fungal growth are different, so that during combine medication, different links of fungal growth are inhibited, and thus a synergy effect is achieved; compared with a single medicine, the medicine composition disclosed by the invention has remarkably-enhanced antibacterial effect, remarkably-reduced dosage, better effect on treating the fungal keratitis and no obvious side effect, thereby providing a novel efficient, broad-spectrum and harmfulless antifungal eye medicine for clinically treating the fungal keratitis in the ophthalmology department. Compared with a single medicine, the medicine composition disclosed by the invention has the advantages of enhancing the antibacterial effect in vitro by eight times, remarkably decreasing the dosage in vivo, remarkably reducing the toxic and side effects and preventing the occurrence of drug resistance.

Description

Technical field: [0001] The invention belongs to medical preparations, in particular to a pharmaceutical composition for treating fungal keratitis. Background technique: [0002] Fungal keratitis is a common suppurative keratopathy with a high rate of blindness. The main pathogens of fungal keratitis in my country are Fusarium and Aspergillus (Fusarium accounts for 70-80% of the total pathogenic bacteria, and Aspergillus accounts for 10-20% of the total pathogenic bacteria). At present, the commercial drugs used to treat fungal keratitis in my country are only natamycin eye drops and fluconazole eye drops. The antibacterial activity of the two eye drops against Fusarium and Aspergillus is low, and the clinical efficacy is poor. , Many patients develop corneal perforation, fungal endophthalmitis, etc. due to ineffective treatment, and are finally forced to enucleate the eyeball, which brings great pain to the patient. Due to the lack of effective drugs, fungal keratitis has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/305A61K31/14A61P31/10A61P27/02
Inventor 徐岩赵东卿庞广仁王天祥魏秋彩
Owner 河南省眼科研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com